Francois Cedric 4

Accession 0001492422-26-000041

CIK 0001492422other

Filed

Jan 20, 7:00 PM ET

Accepted

Jan 21, 4:14 PM ET

Size

9.1 KB

Accession

0001492422-26-000041

AI-generated summary of this filing

Updated Jan 21, 2026

Apellis (APLS) CEO Cedric Francois Sells 8,182 Shares

What Happened

Cedric Francois, CEO of Apellis Pharmaceuticals (APLS), sold 8,182 shares on January 20, 2026 at $19.79 per share, for total proceeds of $161,946. The Form 4 reports the sale as an open‑market/private sale (code S).
The filing notes this sale was made to cover tax withholding on Restricted Stock Units (RSUs) that vested on January 16, 2026 (footnote F1). This is a routine tax‑withholding sale rather than a directional trade.

Key Details

Transaction date: 2026-01-20; price: $19.79; shares sold: 8,182; total value: $161,946.
Purpose: Sale to cover tax withholding on RSUs released Jan 16, 2026 (F1).
Ownership disclosures: Several holdings are reported as held in related irrevocable and family trusts (footnotes F2–F5); the reporting person disclaims beneficial ownership of trust‑held shares except to the extent of pecuniary interest.
Shares owned after transaction: not specified in the provided excerpt of the filing.
Filing/timeliness: Report filed 2026-01-21 for a 2026-01-20 transaction — the filing appears timely. No 10b5‑1 trading plan or other prearranged plan is noted in the provided information.

Context

Sales to cover tax withholding on vested RSUs are common and generally treated as administrative transactions rather than signals about the insider’s view of the stock.
Purchases are often more informative about insider sentiment; this transaction appears routine given the stated tax‑withholding purpose.

Form 4

Period: 2026-01-20

DirectorChief Executive Officer

Transactions

Holdings

Footnotes (5)

[F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 16, 2026.
[F2]The securities are held by The Cedric Francois Irrevocable Trust of 2023 - 2. William V. A. Zorn is the trustee of The Cedric Francois Irrevocable Trust of 2023 - 2. The reporting person disclaims beneficial ownership over the shares held by The Cedric Francois Irrevocable Trust of 2023 - 2 except to the extent of his pecuniary interest therein.
[F3]The securities are held by The Cedric Francois Irrevocable Trust of 2023. William V. A. Zorn is the trustee of The Cedric Francois Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Cedric Francois Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
[F4]The securities are held by The Francois Grossi Trust, for which Juliana Grossi, the spouse of the reporting person, serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Francois Grossi Trust except to the extent of his pecuniary interest therein.
[F5]The securities are held by The Francois-DuBois Educational Trust, for which the Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by The Francois-DuBois Educational Trust except to the extent of his pecuniary interest therein.

Signature

/s/ David Watson, attorney-in-fact for Cedric Francois|2026-01-21

1 file

Apellis Pharmaceuticals, Inc.

CIK 0001492422

Entity typeother